PD-L1 Antikörper

Produktnummer ABIN2665965

Dieses Ratte Monoklonal-Antikörper erkennt spezifisch PD-L1 in FACS. Er zeigt eine Reaktivität gegenüber Maus.

Kurzübersicht für PD-L1 Antikörper (ABIN2665965)

Target: PD-L1 (CD274 (PD-L1))

Reaktivität: Maus

Wirt: Ratte

Klonalität: Monoklonal

Konjugat: Dieser PD-L1 Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS)

Klon: 10F-9G2

Produktdetails anti-PD-L1 Antikörper

Marke: Ultra-LEAF™

Aufreinigung: The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.

Sterilität: 0.2 μm filtered

Endotoxin-Niveau:

Endotoxin level is <0.01 EU/μg of the protein (<0.001 ng/μg of the protein) as determined by the LAL test.

Isotyp: IgG2b kappa

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1.0 mg/mL

Konservierungsmittel: Azide free

Handhabung: This Ultra-LEAF™ solution contains no preservative, handle under aseptic conditions

Lagerung: 4 °C

Informationen zur Lagerung: The antibody solution should be stored undiluted between 2°C and 8°C.

Details zu PD-L1

Target: PD-L1 (CD274 (PD-L1))

Andere Bezeichnung: CD274

Hintergrund: CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. It is expressed on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes. B7-H1 is one of the ligands of PD-1. The interaction of B7-H1 with PD-1 plays an important role in the inhibition of T cell responses. Other studies have shown that B7-H1 is able to costimulate T cell growth and cytokine production. CD274 is involved in costimulation essential for T cell proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-independent manner. Its interaction with PD-1 inhibits T cell proliferation and cytokine production.

Pathways: Cancer Immune Checkpoints